Gael Forterre, Chief Commercial Officer at VolitionRx, noted that the agreement aligns with the company’s broader strategy to out-license its testing technology to established industry players. By leveraging Sysmex’s global installed base and expertise in hemostasis and thrombosis, Volition aims to transition its diagnostic tools from research settings to widespread clinical application.

The optimization phase will focus on adapting the Nu.Q® NETs assay for use on Sysmex platforms. According to internal projections, the total addressable market for this specific diagnostic application stands at $3.8 billion. Beyond initial detection, the companies believe the test could provide a cost-effective solution for continuous patient monitoring, potentially improving clinical decision-making and personalized treatment pathways.